Springer Nature is making SARS-CoV-2 and COVID-19 research free.
View research |
View latest news |
Sign up for updates
From: Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy